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CARDIAC NEOPLASMS: DO EFFECTIVE TREATMENTS EXIST 
 
VANESA BARBARA NOEL 
 
ABSTRACT 
Primary cardiac neoplasms (PCNs) represent the rarest form of neoplastic growths 
worldwide with an incidence ranging from 0.001 – 0.3% in autopsy series (Yu et al., 
2014) (“Primary Cardiac Neoplasms,” 2014). The rarity of these tumors has contributed 
to the challenges associated with their diagnosis and treatment (“Primary Cardiac 
Neoplasms,” 2014). Primary heart tumors are generally classified as benign or malignant 
based on whether or not the tumors cells invade their surrounding tissue. Primary benign 
heart tumors can be further sub-classified as non-complicated or complicated. Non-
complicated tumors are those that are stable, occur alone, and do not invade the cardiac 
conduction system. Conversely, complicated primary benign cardiac neoplasms are those 
that tend to break off into systemic circulation increasing the risk for embolization, have 
multicentered origins within the heart and/ or invade the cardiac conduction system 
which may lead to heart block and sudden death (“Cardiac Tumors: Merck Manual 
Professional,” n.d.). These distinctions have been shown to significantly impact the 
efficacy of treatment. Primary tumors in general tend to involve either the myocardium, 
i.e. the heart muscle itself, or the endocardium; i.e. the membrane that lines the heart 
cavities. In either case, the tumors most often appear in the left atrium (Roberts, 2001). 
Among primary cardiac neoplasms, myxomas (a type of non-cancerous heart tumor) are 
the most common accounting for approximately 40-50% of these growths (“Primary 
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Cardiac Neoplasms,” 2014). Clinicians tend to rely heavily on imaging procedures for the 
diagnosis of primary heart tumors because there are no characteristic clinical signs 
exclusive to primary cardiac neoplasms (Bartoloni & Pucci, 2013). Further, these growths 
have a tendency to mimic the symptomology of other better known conditions such as 
heart failure, stroke, and coronary artery disease (“Cardiac Tumors: Merck Manual 
Professional,” n.d.).   
The mean age of diagnosis for these tumors is approximately 50 years of age but 
many PCNs have been identified in children (Bartoloni & Pucci, 2013; “Primary Cardiac 
Neoplasms,” 2014). Further, sources disagree on the relative incidence of these 
neoplasms among men and women. Some report a higher prevalence in women while 
others hold that the frequencies are equal for both sexes and across all races (Bartoloni & 
Pucci, 2013; “Primary Cardiac Neoplasms,” 2014).  
The standard of care for the treatment of primary cardiac neoplasms are; as with 
other neoplastic conditions; radiation therapy, chemotherapy, surgical resection, and; in 
some instances; cardiac transplantation. However, due to the differences in tumor 
histology, i.e. the structure and molecular characteristics of tumor cells, many of the 
current treatment options available to and considered curative in patients with non-
complicated benign PCNs do not confer the same survival benefits in patients with 
complicated benign PCNs nor in patients with malignant PCNs. With treatment, the 
prognosis associated with primary cardiac neoplasms is heavily dependent upon the type 
of tumor. Primary benign non-complicated neoplasms tend to have very positive 
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prognoses. Even with incomplete resection, reports have shown no evidence of 
recurrence in patients with this tumor type (Jr et al., 1987). On the other hand, primary 
malignant neoplasms of the heart are associated with the poorest prognoses. The longest 
reported median survival time is only 16.5 – 17 months after diagnosis and surgical 
excision of the primary tumor (Chahinian, Gutstein, & Fuster, 2000; Ostrowski, 
Marcinkiewicz, Kośmider, & Jaszewski, 2014; Simpson et al., 2008).  
In this thesis we examine the reported outcomes of the above four forms of 
treatment that are regarded as the standard of care for primary cardiac neoplasms. We do 
this by reviewing the currently available literature characterizing the results of these 
respective courses of therapy. We then evaluate the efficacy of these treatments relative 
the definition of effective treatments developed herein. Finally, based on the evidence, 
we conclude that effective treatments do exist for approximately 38% of people with 
PCNs. This minority represents the people with primary benign non-complicated cardiac 
neoplasms. We also regrettably conclude that for the other 62% (37% with benign 
complicated cardiac neoplasms and 25% with malignant cardiac neoplasms) of people 
with primary cardiac tumors effective treatments do not exist. For this reason, we propose 
the further investigation of two promising therapies. These are cardiac 
autotransplantation and targeted gene therapy. We believe that elucidating the possible 
advantages of these therapies in the heart will lead to treatments that can be deemed 
effective in treating complicated primary benign cardiac neoplasms as well as primary 
malignant cardiac neoplasms.  
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I. INTRODUCTION 
Neoplasms 
Neoplasms, or tumors, are abnormal masses of tissue resulting from the 
dysregulation of cell growth and/ or death. These masses may be benign (non-cancerous) 
or malignant (cancerous). The varied origins of tumors has led to the development of an 
extensive nomenclature aimed at classifying the growths by the tissues in which they 
occur and by their malignancy. The suffix –oma following the cell type is generally used 
to refer to benign growths. There are, however, some malignant tumors and non-tumors 
conditions that have been mistakenly named in this way (“Decoding the ‘-Omas’ - 
Intelihealth,” n.d.). For example, melanomas are very well known malignant disease of 
the skin and glaucoma is simply a condition caused by increased pressure in the eye. 
(“Decoding the ‘-Omas’ - Intelihealth,” n.d.). As seen in Table 1 below, neoplasms may 
derive from primitive embryonic tissue, epithelial ducts and surfaces, and/or from soft 
tissues. Examples of epithelial surfaces and ducts are the skin, the respiratory track, and 
breasts. Bone, lymph vessels, and the heart are all examples of soft tissue. (“Pathology of 
neoplasia for medical education,” n.d.). Growths resembling primitive embryonic tissues 
are named with the ending “-blastoma”. Tumors arising from epithelial surfaces and 
ducts are categorized as carcinomas and those arising from soft tissues are known as 
sarcomas (“Pathology of neoplasia for medical education,” n.d.). 
 
 
 
2 
 
Table 1: Tissue Origins of Common Neoplasms30 * 
Primitive Embryonic 
Tissue 
Epithelial Surfaces 
and Ducts 
Soft Tissues 
Retinoblastoma 
Neuroblastoma 
Hepatoblastoma 
Medulloblastoma 
Squamous cell carcinoma 
of the cervix+  
Adenocarcinoma of the 
stomach+ 
Hepatocellular carcinoma+ 
Renal cell carcinoma+ 
Leiomyosarcoma* 
Chondrosarcoma* 
Osteosarcoma* 
Liposarcoma* 
+ derived from ectoderm or endoderm, * derived from mesoderm adapted from *adapted 
from (“Pathology images and text for medical education - WebPath,” n.d.) 
 
Neoplastic conditions tend to have gender specific predilections and they also 
have a tendency to occur only in certain age and ethnic groups (Figure 1 & 2) (UK, 
2014b). This partiality is often the result of obvious anatomical deviations and/or certain 
hereditary factors. For example, while some men do get breast cancer, it is over 100 times 
more likely to occur in women. On the other hand, lung cancers are more prevalent in 
men and prostate tumors occur exclusively in men. In regards to age, leukemias and brain 
tumors prevail in early childhood while bowel tumors and tumors of the reproductive 
organs tend to occur more in later adulthood (UK, 2014b).  As to race, genetics 
undoubtedly plays a role in the distribution of tumor incidence. By tumor type alone, 
renal neoplasms are more prevalent in the American Indian/Alaskan Native populations, 
pancreatic tumors are more common in African American populations, and ovarian 
cancers occur more often in Caucasian populations (Eheman et al., 2012).  Of note, while 
reports indicate a higher overall prevalence of some neoplasias in Caucasian populations, 
disparities in care have led to higher mortality in minorities (Berz et al., 2009).  
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Figure 1: 5 Most Commonly Diagnosed Cancers in Males by Age47 
Among males certain neoplastic conditions are more prevalent in certain age groups 
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Figure 2: 5 Most Commonly Diagnosed Cancers in Females by Age47 
Among females certain neoplastic conditions are more prevalent in certain age groups 
 
 
The symptomology of neoplasms depend upon the type, size, and location of the 
tumor. Benign growths tend to be more clinically silent than malignant diseases. This is 
of course until they begin to invade vital pathways. Small tumors are less likely to be 
clinically relevant but they do carry an increased risk of thromboembolization. Finally, 
the location of the tumor is important; not only symptomatically but also in consideration 
of the efficacy of certain therapies. For example, renal cell carcinomas are slow growing 
tumors that can reach a considerable size before detection due to the amount of space 
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available in the retroperitoneum (Kumar, Abbas, & Aster, 2012). Conversely, growths 
within the central nervous system often become immediately symptomatic due to the 
confines of the axial skeleton. Any additional mass within the skull or the spinal canal 
will displace and compress vital structures, thus affecting normal function. 
While the exact cause of neoplasms is unknown, many theories, with a reasonable 
amount of supporting evidence, have been set forth. To date, there are two broad and 
widely recognized factors influencing tumor development. These are environmental 
factors, in which the growths are categorized as sporadic, and hereditary predispositions, 
in which they are known as familial neoplastic conditions. (“Neoplasia,” n.d.).  
Environmental factors include carcinogenic chemicals such as acetaldehyde; 
found in alcoholic beverages; cigarette smoke, and outdoor air pollution (“Known and 
Probable Human Carcinogens,” n.d.). Oncogenic viruses are also considered to be 
environmental causes. These include the human papillomavirus (HPV), to which some 
squamous cell carcinomas are attributable, and the hepatitis B virus which has been 
directly linked to the development of hepatocellular carcinomas (“Pathology of neoplasia 
for medical education,” n.d.). Further, radiation; whether it be ultraviolet radiation, X-
rays, or gamma rays; has also been known to promote neoplastic changes within cells. 
Still, other environmental factors such as diet have been linked to the incidence of at least 
one out of every ten cases of neoplasia (UK, 2014a).  
Familial neoplasms occur when a chromosome is inherited with missing or 
defective anti-oncogenes. In many cases, these effected oncogenes seem to carry racial 
predilections (“Pathology of neoplasia for medical education,” n.d.). The causes of 
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hereditary tumors are just as numerous, if not more so, as the environmental causes. 
However, the variation comes not in the mode of damage but rather in the gene that is 
altered.  For instance, a mutation in either the HER2 oncogene or the BRCA-1 oncogene 
can potentially lead to the development of breast cancer (Table 2). Furthermore, 
mutations in p53 typically manifest as a host of tumors which distribute themselves 
without prejudice throughout the body in a condition known as Li Fraumeni syndrome. 
Familial neoplastic conditions tend to be more aggressive physiologically and thus more 
difficult to treat clinically. Fortunately, these inherited forms only account for 
approximately 10-15 % of all cases.  Due to the variations in the mode of damage and in 
the segments of DNA that can be affected, each of these causes, whether environmental 
or hereditary, has its implications in the progression of the disease states.  
 
 
Table 2: Oncogenes and their Associated Neoplasms27* Neoplasias can be the result of 
hereditary mutations in a variety of genes  
Oncogene Associated Tumors (benign & malignant) 
HER2 Breast and Ovarian Carcinomas 
RAS Various Carcinomas and Leukemias 
C-MYC Lymphomas 
BRCA-1 Breast & Ovarian Carcinomas 
APC Colonic adenocarcinomas 
p53 Various, many carcinomas 
BCL-2 Chronic lymphocytic leukemia, lymphomas 
*Adapted from (“Neoplasia,” n.d.) 
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Regardless of etiology, neoplasms are characterized by an inauguratory incident 
of damage to a cell’s genetic material. If this damage is left unchecked, it will cause the 
cell to progress through a series of steps in which the cell will acquire or lose the 
machinery necessary to evade the normal cell cycle. These steps may involve insertions, 
deletions, or translocations of entire sections of DNA in a process known as 
transformation. Once transformation has taken place cells are said to have “escaped” 
from the bounds of normal physiological regulation and control. This loss of control 
manifests as either an increase in the proliferation of affected cells or a decrease in their 
natural cell death (Kumar et al., 2012).   
 
In the Heart 
As tumors go, cardiac neoplasms represent the rarest form worldwide with an 
incidence of ranging from 0.001 – 0.3% in autopsy series (Yu et al., 2014). This 
represents, as reported by Reynen in 1995, approximately 17 – 2,800 primary heart 
tumors in every million autopsies (Reynen, 1995). While the percentages may sound 
dismissively small, in a world of roughly six billion people it may represent 
approximately 60 million lives affected by this potentially devastating disease. Heart 
tumors may be either primary, originating in heart, or secondary, a result of metastasis 
from distant tissue sites (Kumar et al., 2012). Primary tumors can also be further 
classified as benign or malignant with benign primary cardiac tumors accounting for 
more than three quarters of all primary cases (Meng et al., 2002).   
Although we tend to think of benign tumors as innocuous, in the heart they can 
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lead to significant morbidity and mortality by obstructing circulation, invading the 
cardiac conduction system, and by the formation of thromboemboli (“Cardiac Tumors: 
Merck Manual Professional,” n.d.; Meng et al., 2002). On the other hand, while primary 
malignant tumors occur a great deal less frequently than benign growths, their death toll 
is no less pervasive. The difficulty associated with treating these more aggressive tumor 
types result in a greater overall rate of mortality (Leja, Shah, & Reardon, 2011). Also, 
relative to extracardiac malignancies, the prognosis associated with malignant heart 
tumors remains very poor (Simpson et al., 2008). As measured by Hamidi and her 
colleagues, the median survival in patients with primary cardiac sarcomas; the most 
common form of primary malignant cardiac neoplasms; was 6 months. This was 
significantly less than the 93 months reported as the median survival in patients with non-
cardiac sarcomas (Hamidi, Moody, Weigel, & Kozak, 2010).  
 
Chahinian et al report that the first primary cardiac tumor was described in 1845 
(Chahinian et al., 2000). Before the 1930s primary tumors of the heart were still 
considered a rarity and a post mortem diagnostic event (Meng et al., 2002). Antemortem 
identification of these tumors did not occur until 1934, 30 years after the invention of the 
echocardiogram (Meng et al., 2002).Since that time, many other primary cardiac tumors 
have been identified and characterized. Today, as seen in Table 3, we have over 20 types 
of primary cardiac neoplasms with approximately half of these being characterized as 
malignant (Silverman, 1980).  
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Table 3: Classification of Primary Cardiac Tumors43*  
Classification 
 Benign (75%) 
     myxoma (50%,) 
     rhabdomyoma (20%) 
     Lambl's excrescence 
     fibroma 
     lipoma 
     hemangioma 
     lymphangioma 
     mesothelioma 
     teratoma 
     thyroid adenoma 
     chemodectoma 
     neurilemmoma 
    ganglioneuroma 
    valve cyst     
    granular cell myoblastoma 
Malignant (25%) 
    sarcoma (20%) 
       angiosarcoma 
       hemangioendotheliosarcoma 
       Kaposi's sarcoma 
       rhabdomyosarcoma 
       leiomyosarcoma 
       osteosarcoma 
       chondrosarcoma 
       neurogenic sarcoma 
   lymphoma 
   plasmacytoma 
   mesenchymoma 
 
*Adopted from (Silverman, 1980) 
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While myxomas represent the most common primary, benign cardiac neoplasm, 
there are over 10 other nonmyxomatous benign primary tumor types. Nonmyxomatous 
lesions have a tendency to be harder to treat than myxomas. These lesions may be 
considered complicated by virtue of their histology, their location within the heart, or 
their tendency to become unstable. These include rhabdomyomas, lipomas, and 
mesotheliomas; among others (Table 3) (Silverman, 1980). Unlike patients with 
myxomas, patients with these other tumor types do not as readily benefit from 
conventional treatment. For example, rhabdomyomas are notoriously associated with 
poor prognoses. Despite the benign histology of these tumors, their tendency to occur in 
clusters, their poor encapsulation, and deep myocardial location make surgical resection 
difficult; if not impossible (Silverman, 1980). Neither are lipomas, half of which arise 
from the subendocardium, easily excised. Further those originating from the heart valves 
are only treated by complete valve excision and prosthetic replacement. Additionally, 
surgical resection of primary cardiac mesotheliomas has not even been attempted. These 
benign lesions arise selectively from the atrioventricular node and are known to cause 
sudden death as a result of compete heart block (Silverman, 1980). Still other benign 
tumors have been deemed surgically unresectable and in others radiation and 
chemotherapy has not been efficacious.  
The invention of modern diagnostic techniques like the echocardiogram, along 
with advances in cardiac surgical procedures, have turned primary cardiac tumors from a 
disease rarely diagnosed before autopsy into a condition potentially curable given the 
right conditions (Centofanti et al., 1999). With the advent of echocardiography clinicians 
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were able to visualize the chambers and tumors of the heart in vivo. Since then, 
echocardiography has proven the most useful tool in terms of the diagnosis of cardiac 
tumors (Tj, 2000). In practice, clinicians have been able to locate and define the extent of 
cardiac tumors using echocardiography (Tj, 2000). Further, other types of diagnostic 
imaging such as Magnetic Resonance Imaging (MRI) has been useful in identifying 
cardiac tumor cell types (Tj, 2000). Today, myxomas  are recognized as the most 
common primary benign tumor of the heart while sarcomas represent the most common 
primary malignant cardiac disease (Sarjeant, Butany, & Cusimano, 2003). Despite these 
advances, the rarity of primary cardiac tumors has been the primary contributor to the 
challenges associated with their diagnosis and treatment (“Primary Cardiac Neoplasms,” 
2014). 
Demographically, sources disagree on the relative incidence of primary cardiac 
neoplasms (PCNs) among men and women. While some report a higher prevalence in 
women, others hold that the frequencies are equal for both sexes and across all races 
(Bartoloni & Pucci, 2013; “Primary Cardiac Neoplasms,” 2014). Despite the lack of 
definitive demographic characterizations with regards to gender, investigators have noted 
that specific types of primary cardiac tumors tend to affect certain areas of the heart and 
occur predominately in certain age groups (Table 4) (“Cardiac Tumors: Merck Manual 
Professional,” n.d.). For example, 90% of Rhabdomyomas, a primary benign tumor, 
occur in children and are found intramurally within the septum or free wall of the left 
ventricle. Conversely, sarcomas, a primary malignant tumor, affect mostly middle aged 
adults and originate in the atrium generally involving the pericardium (“Cardiac Tumors: 
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Merck Manual Professional,” n.d.).  
 
Table 4: Types and Sites of Cardiac Tumors5 Examples of tumors and where they 
occur in the heart. 
Type Examples Site 
Benign Primary Tumors Myxomas Left Atrium 
Papillary fibroelastoma Aortic and  Mitral Valves 
Rhabdomyomas Septum or Free Wall of Left 
Ventricle 
Malignant Primary Tumors Sarcomas Right atrium and pericardium 
Pericardial Mesothelioma Pericardium 
Primary Lymphomas Right atrium & right ventricle 
  *Soft tissues: cartilage, bone, fascia, smooth & skeletal muscle, blood & lymph vessels etc. 
 
 
The morphologies of cardiac neoplasms also vary. Tumor shapes range from 
pedunculated to sessile, or flat, and from solid and stable to friable with increased risk of 
systemic embolization (“Cardiac Tumors: Merck Manual Professional,” n.d.). Due to the 
varied morphology and originating locations of these tumors, their symptomology is also 
characterized by a considerable amount of variation. Patients may experience anything 
from arrhythmias and sudden death to being completely asymptomatic with a lesion that 
is not detected until examinations are performed for other reasons (“Cardiac Tumors: 
Merck Manual Professional,” n.d.). 
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What’s missing? 
In short, while primary cardiac neoplasms (PCNs) are clinically significant 
lesions with potentially life threatening consequences that affect patients of all ages, 
many sources report no statistically significant difference between the survival of patients 
with complicated benign lesions or malignant lesions who received treatment and those 
who did not (Meng et al., 2002; Yu et al., 2014). More than this, cardiac neoplasms often 
remain clinically silent or present with symptoms similar to those of other cardiac 
diseases. For this reason, the majority of these tumors are diagnosed in late or advanced 
stages where the efficacy and availability of therapies are known to be limited 
(Perchinsky et al., 1997; Simpson et al., 2008). Further while, many primary heart tumors 
appear to be impartial, having no apparent predilection for race, age, nor gender, over 150 
years after the discovery of the first cardiac there is still very little, if any, complete 
demographic descriptions of the incidence and prevalence of the diseases in live 
populations. Undoubtedly a function of the rarity and complexity of cardiac tumors, 
many sources offer conflicting information presented in dissimilar ways which make 
comparison challenging. Moreover, for many primary complicated benign tumors and 
primary malignant tumors, standard treatments are aimed largely at prolonging life rather 
than eradicating the disease. Despite this, to our knowledge, there has been no 
comprehensive evaluation of the quality of longer life these patients live as a result of the 
palliative treatment. Thus, with no complete national or worldwide demographic 
characterization on the prevalence and incidence of primary cardiac neoplasms in vivo; 
no universally accepted notion of best practice in their treatment; and no documentation 
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of patient quality of life pre- and post- treatment; this begs the question; do effective 
treatments exist for primary tumors of the heart? 
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II. SPECIFIC AIMS 
While the rarity of primary cardiac neoplasms is undoubtedly the primary 
contributor, it is clear that there is a lack of consensus among researchers regarding 
certain aspects of the disease. Current literature often provides contradictory information 
about the prevalence, incidence, and mortality of these tumors. In addition, studies that 
have included subject demographic information and have drawn conclusions on the most 
effective forms of treatment were done in very specific populations which makes 
generalizations very difficult.  Most importantly, while various treatment options for 
primary cardiac neoplasms exist, their efficacy in the treatment of certain tumor types 
remains questionable. 
Thus, the goal of this study is to determine whether the treatment options available 
for both benign and malignant primary cardiac neoplasms can be considered effective. 
Specifically we will; 
 Provide a working definition of Effective Treatment 
 Review literature published on the outcomes associated with four “standard of 
care” treatments for primary cardiac neoplasms 
 Evaluate the efficacy of each treatment relative to the given definition 
It is our hope to establish whether or not the standard of care treatments for primary 
cardiac neoplasms can be considered effective taking into account the risks and benefits 
of the respective therapies. In the end, we propose the further investigation and 
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implementation of promising and innovative therapies that could, if proven effective, lead 
to a significant decrease in the overall number of cardiac cancer related deaths. 
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III. REVIEW 
 
Define: Effective Treatment 
For the purposes of this paper we adapt the National Library of Medicine’s 
definition of effective treatment. First, an effective treatment is one that alleviates the 
associated symptoms of the disease. In everyday life, as well as in published literature, 
we see symptom relief at the top of patient reported concerns (Df, 1995). Therefore, to be 
considered effective, targeted therapies must address patient reported symptoms. Further, 
effective treatments should be shown to increase patient survival rates in a way that is 
significantly greater than patients who do not receive treatment. If administered 
treatments do not significantly improve survival beyond what is attainable with no 
treatment, then we risk venturing into the dimensions of undue trauma. Accordingly, 
effective therapies must not cause any undue trauma. Understandably, there are cases in 
which the actual survival benefit is relatively small or otherwise unknown. In these cases, 
as is common practice, patients should decide whether the possibility of a longer life is 
worth the certainty of pain and discomfort. Last, effective treatments for primary cardiac 
neoplasms should result in a post-treatment quality of life that is greater than what would 
be the patient’s quality of life without treatment. This, we say, includes rapid recovery. 
Quick recovery is essential to a greater quality of life because patients should be allowed 
to painlessly enjoy most of the time they have been given. In the end, we choose these to 
constitute our definition of effective treatment because these outcomes are, above all, 
patient centered. Patient centered outcomes are the outcomes that have been shown to 
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matter most to patients and to influence patient satisfaction with providers and with 
health care delivery as measured using Health Quality of Life surveys (Fleurence, 2012). 
As the inauguration of the Patient Centered Outcomes Research Institute (PCORI) in 
2010 would show, patient centered outcomes in clinical effectiveness research has 
become a priority.  Finally, we note here, that for different therapies these definitions of 
effective treatment may be mutually exclusive. We understand and consider that while 
some treatments can improve a patient’s quality of life, they will not necessarily confer 
longevity. 
 
Treatment Options 
Currently there exists four standard treatments for primary cardiac neoplasias. 
These are radiation therapy, chemotherapy, surgical excision, and heart transplantation. 
These therapies, individually and together, are used to treat neoplasias in many different 
organ systems; not just in the heart. Heart transplantation, while not routinely considered 
as a primary form of treatment for primary cardiac neoplasms, it is used extensively to 
treat many of the other heart disease whose symptoms PCNs tend to mimic. Thus, we 
consider it here to gauge the possible advantages in the treatment of primary heart 
tumors. While these treatments overall represent the standard of care for most cancers, 
when it comes to the heart, some of these therapies may prove more toxic than curative. 
For some of these, their toxicity can be felt throughout the body almost immediately and 
any collateral damage appears before the inciting pathogen can be deemed eradicated. 
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For others, the wounds remain relatively superficial and damage is localized to the 
cardiovascular system. The heart, though lauded for its adaptability, is quite sensitive to 
the noxious agents and the considerable amount of trauma associated with standard 
treatment (Roberts, 2001). Moreover, for certain tissue types, these therapies have not 
been shown to confer any increased survival (Butany et al., 2005). These noxious effects 
may tip the scale in regards to the overall effectiveness of the respective treatments. In 
these cases, with no clear answers regarding best practice, traditionally, the value in such 
measures are determined by individuals and their providers. We present these therapies 
here from the least to the most invasive, irrespective of the possible adverse effects 
associated with each. 
 
Option One: Radiation Therapy 
 Radiation therapy, or radiotherapy (RT), uses high-energy radiation in the form of 
X-rays, gamma rays or other charged particles to kill cancer cells by targeting their DNA 
(Figure 3)(“IRT,” n.d.). Unfortunately, the effects of these rays are also felt by all of the 
surrounding normal tissue cells. This ultimately leads to the side effects associated with 
radiotherapy (“Radiation Therapy for Cancer,” n.d.). Radiation therapy can be delivered 
externally in which a machine is position to irradiate the desired location on the patient’s 
body. This type of radiation is known as ‘external beam radiation therapy’ (“Radiation 
Therapy for Cancer,” n.d.). On the other hand radiation may be delivered internally, in 
which radioactive substances are placed in the body and travel in the blood to attack and 
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kill cancerous cells (“Radiation Therapy for Cancer,” n.d.). This type of radiation is often 
referred to as ‘internal radiation therapy’ or ‘implant radiation therapy’ (“Radiation 
Therapy for Cancer,” n.d.). 
 
Figure 3: Radiation’s Effect on Cancer Cells18 Radiation fights cancer by targeting the 
cell’s DNA (adopted from Nawroth, 2008).  
 
Today, the benefits or efficacy of radiation therapy in patients with cardiac tumors 
is still largely unknown. The literature is eerily silent in this regard. This is no doubt in 
some ways a consequence of the low number of people affected by this form of heart 
disease. Still, none have been able to elucidate and/nor demonstrate the benefits of 
radiotherapy in this rare form of heart disease. All who have tried have come away with 
more reasons why radiation to the heart may do more harm than good. While admitting 
that the numbers were too small to be conclusive, Simpson et al report that the role of 
radiotherapy alone or in adjuvant is, at best, limited (Simpson et al., 2008). They note that 
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the effective dose used to treat extracardiac tumors is poorly tolerated by the heart and is 
thus not useful (Simpson et al., 2008). Further, as reported by Butany and his colleagues, 
what would be considered an effective dose in the heart is more likely to cause a serious 
radiation cardiomyopathy or chronic inflammation of the membrane lining the outside of 
the heart (Butany et al., 2005). Among these adverse effects, investigators have also 
noted cardiac hemorrhage and cardiac infection as consequences of radiotherapy used to 
treat cardiac neoplasms (Roberts, 2001). In sum, Butany and his team reported that the 
value of radiation therapy in the heart is limited due to the heart’s sensitivity to the 
specific types of radiation injury noted above (Butany et al., 2005). Further, they state 
that there is only anecdotal evidence to suggest that radiation therapy may be useful in 
preventing local tumor recurrence after complete excision (Butany et al., 2005). Despite 
this, these possible beneficial effects have not been studied or reproduced in any 
significant way. 
Despite the unpromising findings of Butany and his team, Hamidi and her 
colleagues set out to discover what, if any benefit, lay in radiation therapy for primary 
malignant cardiac tumors. In 2010 they released a report featuring 210 patients diagnosed 
with primary cardiac sarcomas, the most common PCN, focusing on the outcomes of 
radiotherapy. Their study, retrospective in nature, also compared intra-cardiac sarcomas, 
to extracardiac sarcomas. The comparison was done with regards to all aspects related to 
patient, tumor, and treatment factors affecting outcome. What they found was that 
radiation therapy, was not an effective primary treatment for primary malignant cardiac 
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tumors and that adjuvant RT conferred no statistically significant survival advantage 
(Hamidi et al., 2010).  
 
Option Two: Chemotherapy 
 
Chemotherapy is the use of medications to fight cancer or prevent pre-cancerous 
growths. It is a generalized treatment that targets and kills rapidly dividing cells.  
Chemotherapy was first used to treat cancer in the 1950s and today there are over 100 
cancer chemotherapy drugs available. The object of these drugs is to fight cancer by 
blocking different functions associated with cell growth and replication (Figure 4) 
(Zitvogel, Apetoh, Ghiringhelli, & Kroemer, 2008). For example, alkylating agents work 
by blocking DNA replication which interferes with cell growth. On the other hand, 
Nitrosoureas interfere with the enzymes that repair DNA. The specific medication used to 
treat a cancer is decided by the prescribing physician and depends on several factors. 
These include the type, stage, grade, and histology of the tumor as well as the patient’s 
age and the presence of comorbidities (“Deciding which chemotherapy drugs to use,” 
n.d.). 
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Figure 4: Chemotherapy’s Effect on Cancer Cells49 Chemotherapy targets various 
functions related to cell growth and replication. 
 
 
Fortunately, for patients and providers alike, much more has been published in 
regards to the efficacy of chemotherapy in the treatment of primary cardiac neoplasms. 
Due to the general success of surgical excision in the treatment of non-complicated 
benign PCNs and the potential for cardiac toxicity, chemotherapy, as with radiation, is 
usually not warranted nor considered for patients with these tumor types (Roberts, 2001). 
In some cases though, chemotherapy has been shown to be of use in reducing the overall 
size of benign neoplasms in preparation for surgical resection (Butany et al., 2005). 
Generally, however, surgical removal of the primary tumor is usually successful and 
patients with these types of tumors are simply monitored with echocardiography for 
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approximately 5-6 years to rule out recurrence (“Cardiac Tumors: Merck Manual 
Professional,” n.d.). However, in the cases of patients with complicated benign PCNs, 
where complete surgical resection is usually not achievable, the potential benefits of 
chemotherapy has not previously been completely characterized. On the other hand while 
chemotherapy’s effects on malignant PCNs have been characterized the results are not 
favorable.  
 In 1991 Putnam et al released a report featuring 21 patients with primary 
malignant heart tumors. Noting that there was no unequivocal evidence regarding the 
benefits of adjuvant chemotherapy, the authors set out to resolve this issue. Their findings 
were not unlike what other studies had shown. What they found is that postoperative 
chemotherapy did not enhance survival in patients with incomplete surgical resections; 
which is usually the case with malignant tumors (Putnam Jr et al., 1991). Moreover, in 
1998, after analyzing the cases of 15 patients, ages 16-66, undergoing adjuvant 
chemotherapy for non-metastatic primary malignant cardiac tumors, Llombart-Cussac 
and his team concluded that chemotherapy had failed to modify the progression of the 
diseases (Llombart-Cussac et al., 1998). This conclusion came after 13 of the 15 (87%) 
had a recurrence of the tumor with five (33%) of those occurring during active treatment 
(Llombart-Cussac et al., 1998). The authors reported that median time to disease 
progression was approximately 10 months with some occurring in as little as 3 months. 
Going further than both Putnam and Llombart-Cussac et al, Butany and his team, 
in their 2005 article, noted no survival benefit of adjuvant chemotherapy for any adult 
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soft tissue sarcoma; less in the heart (Butany et al., 2005). This is most probably due to 
the fact that many chemotherapy agents are not only cytotoxic but are also radiation 
sensitizers i.e. they make the heart more susceptible than usual to the adverse effects of 
the high intensity beams of radiotherapy (Butany et al., 2005). Further, the toxic effect of 
chemotherapy agents on the heart have been shown to manifest themselves in many 
ways. On such way is via impaired left ventricular systolic function (Roberts, 2001).  
In sum, when needed, chemotherapy may be used both pre- and post- operatively 
to successfully treat benign primary cardiac neoplasias.  However, with respect to 
primary malignant cardiac neoplasias the role of chemotherapy as a primary form of 
treatment or as an adjuvant therapy remains poorly defined (Hamidi et al., 2010). Thus, 
the prognosis for patients afflicted with these subtypes remain dismal.  
 
Option Three: Surgical Excision/Resection  
While neoplastic conditions of the heart had been recognized as a human infirmity 
for over 450 years, the first successful resection of a primary cardiac tumor did not take 
place until 1951 (Silverman, 1980).  From then it would be another 57 years before 
Elbardissi and his colleagues would publish the first comprehensive study examining the 
long term survival characteristics of patients whose primary cardiac tumors were treated 
with surgical resection (ElBardissi et al., 2008). Before this, between 1951 and 2008, 
most studies focused on the pathologic and epidemiologic characteristic of the disease 
while only a few focused on the outcomes of treatment (Majano-Lainez, 1997; Meng et 
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al., 2002; Reynen, 1995). The efforts of these studies would later be spurred by 
Shattenberg’s introduction of echocardiography in 1986 as a reliable imaging technique 
for cardiac tumors as well as by other technological advancements in diagnosis and 
surgery (Silverman, 1980).   
Elbardissi’s study synthesizes 48 years of experience with the surgical treatment 
of primary cardiac neoplasms. They analyzed the cases of 323 patients and reaffirmed, in 
their report, the notion of surgical excision as a viable and highly successful option for 
patients with benign non-complicated diseases. However, the authors did note a group of 
non-myxoma benign tumors, those with complicated histologies, which still had 
uncharacteristically low prognoses following surgical excision. The mortality rate in 
these patients with non-myxoma primary benign cardiac tumors was 3.7 times the 
mortality rate of similar patients with myxomas (ElBardissi et al., 2008).  Further, 
Elbardissi’s report also delivered the morose affirmation of the incurable nature of 
primary malignant cardiac diseases. With this data in hand the authors quantified the 
relative survival risk to patients with differing cardiac growths with respect to cardiac 
myxomas; a benign tumor which represents the most common and surgically curable 
PCN (Figure 5) (ElBardissi et al., 2008). In this figure, the x-axis represents study follow 
up in years extending out to 38 years with a mean follow up of 6.16± 6.88 years. The y-
axis represents the likelihood of patient’s survival based on their specific type of primary 
cardiac tumors as compared to patients with myxomas. As can be seen, the survival risks 
to patients whose tumor subtype was something other than a myxoma is both clinically 
and statistically significant. 
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Figure 5. Proportional Hazards Estimate of Tumor Subtypes13 Patients with other 
types of PCNs had poor long term survival than patients with myxomas.  
 
 
Prior to 2008, studies focusing specifically on the surgical outcomes of patients 
with malignant PCNs are almost non-existent. The reports that do feature this tumor 
subtype are mostly case reports and reviews in which benign cardiac tumors dominate 
(Simpson et al., 2008). Fortunately, sensing the need, Simpson et al published a study 
focusing specifically on malignant primary cardiac tumors. As stated previously, while 
these traditionally cureless growths represent the minority of primary cardiac neoplasms, 
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they are also the most lethal with death occurring in up to 6 months without treatment 
(Simpson et al., 2008). However essential this study was to the advancement of the field, 
it offered no more hope to patients with malignant PCNs. Simpson featured the cases of 
34 patients seen for primary malignant cardiac neoplasms in the Mayo clinic over a 32 
year period. Of these, 23 underwent attempted resection with only 15 (65%) being 
complete. Among these 15 patients, the median survival was only 17 months after 
complete surgical excision which was significantly (P=0.01) more than the median 
survival of just 6 months seen in patients in whom complete resection was not achieved 
(Simpson et al., 2008). In the end, all patients eventually died from the progression of 
their disease. This outcome highlights the stark and grim fate of patients afflicted with 
malignant PCNs. It is representative of the larger population treated with surgical 
intervention for malignant primary cardiac neoplasms. With these grim findings, Simpson 
issued a call to action stating that the field required innovative treatment strategies if 
these more aggressive and advance staged tumors were ever to be adequately addressed.  
As reported by Butany et al in their 2005 article, it seems that only patients with 
complete surgical excision of the primary tumors have a real chance at survival. 
However, in practice, for complicated benign and malignant primary tumors, widely clear 
margins are rarely achieved and local recurrence is more common than not (Butany et al., 
2005). Moreover, like Elbardissi and his colleagues, Simpson’s team produced survival 
curves that not only elucidates the poorer survival of patients with malignant disease but 
also depicts the poorer survival of patients in whom complete surgical resection was not 
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possible as is the case with complicated benign primary tumors (Figure 6 & 7) (Simpson 
et al., 2008). 
 
 
 
Figure 6: Survival with Metastatic & Non-Metastatic Disease44* Patient who have 
non-metastatic PCN at the time of presentation tend to have better overall survival 
*adapted from(Simpson et al., 2008) 
 
Metastatic 
Non-Metastatic 
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Figure 7: Survival With and Without Complete Tumor Resection44* Patients in 
whom complete surgical excision was achieved had better overall survival *adapted from 
(Simpson et al., 2008) 
 
Today surgical excision remains treatment of choice for cardiologist in regards to 
heart tumors. In addition, survival prognosis is based heavily upon whether the presenting 
growth is deemed resectable or unresectable. This is primarily because for specific PCNs 
surgical excision has been shown to be extremely effective. For example, the survival of 
patients after the resection of a primary cardiac myxoma is not significantly different 
from the general populace when these numbers are adjusted for age and gender 
(ElBardissi et al., 2008). Thus, when it works, surgical excision is considered the gold 
Complete Resection 
Incomplete resection 
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standard of neoplastic therapies. However for the subset of patients with malignant 
disease, due to the trauma associated with surgery and the fact that surgery has not been 
shown to confer any additional survival advantage, the risks in this case may just 
outweigh the benefits.  
 
Option Four: Orthotopic Heart Transplantation 
Orthotopic heart transplantation (OHT) is the process of replacing a recipient’s 
heart with a donor heart. This is in contrast to the other less common procedure known as 
heterotopic heart transplantation where the recipient’s heart is simply connected or 
‘piggybacked’ onto a donor heart that can act as a backup or assist device should the 
patient need it. For our purposes the latter procedure would be fallacious since the 
recipient‘s own heart is the source of the disease we are trying to remove from the body. 
Accordingly, in this thesis OHT is often simply referred to heart transplantation.   
Before and after cardiac transplantation, recipients receive immunosuppressive or 
anti-rejection drugs, some in the form of corticosteroids, to ensure the proper assimilation 
of the donor heart as a functioning part of its new body. However, because of the need for 
this immunosuppression following transplant, OHT has not routinely been considered for 
patients with neoplastic conditions of the heart because of the increased possibility of 
tumor recurrence and the possibility of immunosuppression stimulating further tumor 
growth (Gowdamarajan & Michler, 2000). Further, some clinicians are weary of using 
heart transplantation as a primary course of treatment for PCN because prolonged 
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exposure to corticosteroids, given to some patients as the first form of 
immunosuppression following transplantation, has been shown to produce cardiac 
adiposity or “the corticosteroid treated heart” (Lindenfeld et al., 2004; Roberts, 2001). 
This condition, in which excessive amounts of fat are deposited in the heart, can stimulate 
pericardial effusion (Roberts, 2001). Still others, assert that OHT may not be a viable 
option for patients with neoplastic heart conditions for reasons outside of the pathology 
of the disease. They hold that the paucity of available heart donors would limit providers’ 
acceptance of OHT as a viable form of management (Hamidi et al., 2010). If true, heart 
transplantation would be deemed an unreliable, if inadequate, form of treatment. 
Orthotopic heart transplants are generally not performed in patients with benign, 
non-complicated cardiac neoplasms. As previously stated, In these cases the primary 
surgery is considered curative (Sarjeant et al., 2003). However, when these ‘benign’ 
growths begin to impede upon systemic blood flow, cardiac conduction or become 
dangerously unstable, as is the case with complex benign PCNs, heart transplantation has 
been shown to confer a significant survival benefit to these patients (Gowdamarajan & 
Michler, 2000). The median survival of the patients in this report with benign PCNs 
which were considered inoperable, was 46 months.  
 As early as 1987 researchers and clinicians, were calling for the further 
investigation of orthotopic heart transplantation as an alternative therapy for patients with 
primary cardiac neoplasms. It was not until 1990, however, that Siebenmann et al 
featured the case of a patient with a primary synovial sarcoma of the heart. Five years 
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later, in 1995, Goldstein et al released a study featuring eight patients undergoing OHT 
for their unresectable heart tumors. Four of these patients had malignant primary cardiac 
tumors and the other four had locally invasive neoplasms at the time of diagnosis. Their 
findings were promising. The authors reported that in patients whose heart transplant was 
completed with tumor free or negative surgical margins,  i.e. 6 of the 8, OHT conferred 
long term survival (range 14-78 month) without tumor recurrence despite 
immunosuppression. On the other hand, the two patients in whom tumor free surgical 
margins were not attainable (i.e. positive margins) did not reap the survival benefits of 
the procedure despite receiving adjuvant chemotherapy (Dj, Mc, Ea, P, & Re, 1994). The 
authors saw this as evidence of the great potential of orthotopic heart transplantation and 
noted the further need for investigation.  
With the paucity of cases to examine it would be another 5 years before 
Gowdamarajan et al could publish a study featuring enough patients with various tumors 
histologies to make their findings generalizable. Their findings were less auspicious 
however. Of the 28 patients included in this study 7 had tumors with benign histology 
and 21 had malignant diseases. All patients underwent orthotopic heart transplant as their 
primary form of treatment (Gowdamarajan & Michler, 2000). What they found is that 
patients with benign tumors greatly benefited from the procedure in that their overall 
postoperative survival was longer than the patients with malignant diseases. The median 
survival for their patients with benign primary cardiac tumors was 46 months compare to 
only 12 months in their patients with malignant primary cardiac tumors (Gowdamarajan 
& Michler, 2000). Of note, the authors did not report on the condition of the surgical 
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margins. With no apparent benefit to report for patients with malignant tumors the 
authors concluded that the role of transplantation in these patients remained unclear and 
that further experience and follow up was needed (Gowdamarajan & Michler, 2000). 
In 2003, Jiménez-Mazuecos and his colleagues released an article to specifically 
answer the question of whether or not orthotopic heart transplant was a viable therapeutic 
option for primary cardiac neoplasias. Their study focused more specifically on cardiac 
sarcomas which are the most common malignant PCN and the tumor type most treated by 
OHT (Mazuecos et al., 2003). The study featured the case of eight patients of which, after 
screening, only six were deemed suitable for the procedure. These six were the ones who 
had no detectable extracardiac extension of the primary tumor as seen on pre-surgical 
echocardiography and/or computed tomography. Aside from the very low patient 
population, one of the greatest limitations the authors noted with this study is the 
inadequacy of current imaging techniques to detect extracardiac extension before surgery. 
Once in the operating room, following thoracotomy, three of the six patients deemed 
eligible in the beginning, were found to have obvious extracardiac extension of the 
primary tumor (Mazuecos et al., 2003). In these cases the surgical team could not 
continue with the transplants. In the end, the authors found that not only was survival in 
patients who received orthotopic heart transplants similar to other patients with primary 
cardiac sarcomas who received conventional treatment; i.e. surgical excision, 
radiotherapy, and chemotherapy; but also that survival rates did not significantly differ 
from those patients in whom no orthotopic heart transplant was performed (Mazuecos et 
al., 2003). Further, the authors note that their data seem to indicate that the specific 
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histology of the primary malignant tumor is more important than the mere presence of a 
malignant disease in deciding whether or not to perform a heart transplant. This 
conclusion came after noting that subjects with less aggressive tumor types had higher 
survival rates than those with more aggressive tumor histologies. Thus, they report, the 
presence of an angiosarcoma, aggressive in nature due to its high vascularity, would be a 
contraindication to OHT whereas the presence of a less aggressive tumor such as a 
rabdomyosarcoma might make OHT a more viable option (Mazuecos et al., 2003). 
Despite these unfavorable findings, in response to Hamidi’s misgivings about the 
availability of heart donors, Jiménez-Mazuecos and his team reported that the average 
time from inclusion on the transplant waiting list to the actual procedure was only 34 
days; with a range of 8 to 48 days (Mazuecos et al., 2003). This suggests that if OHT had 
been shown to be effective in treating certain types of PCNs then the supply of hearts 
would be enough to meet the demands for transplant.  
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IV. CONCLUSION 
Primary cardiac neoplasms (PCNs) are rare. We see this reflected in the paucity of 
reports published about these neoplastic heart conditions. Additionally, even in the 
studies that have been published, one of the greatest limitations is the small sample size. 
The lack of subject data available for analysis has greatly limited the generalizability and 
replicability of the studies. The rarity of PCNs is further reflected in the general lack of 
success in their early diagnosis. Both, Silverman, in his 1980 report, and Majano-Lainez, 
17 years later, agreed that a that a high level of clinical suspicion and expertise is 
necessary to effectively and efficiently diagnose these protean disorders (Silverman, 
1980) (Majano-Lainez, 1997). The invention of many diagnostic imaging techniques has 
in many ways aided physicians in this regard (Silverman, 1980). However, once 
clinicians arrive at a definitive diagnosis, the question still remains; do effective 
treatments exist for these patients? In 1999, Centofanti and his colleagues suggested that 
the answer may be subject to a tumor type effect that is still very much apparent today.  
Patients whose cardiac neoplasms are benign, non-complicated lesions such as 
myxomas, are given the greatest positive prognosis. In almost all instances these patients 
appear to reap the greatest benefits from conventional therapy. First, radiation and 
chemotherapy are usually not warranted with these types of tumors. This is because these 
tumor types are more often than not successfully managed with surgery (Sarjeant et al., 
2003). Further, because of the potential for adverse effects, these treatments are often 
times contraindicated (Butany et al., 2005; Hamidi et al., 2010; Roberts, 2001). In some 
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cases, however, when it is need chemotherapy has been shown to be useful as a 
neoadjuvant treatment to shrink the indicated tumor in preparation for surgery. Radiation 
therapy, on the other hand, has not been shown to effectively reduce tumor size prior to 
surgical excision; thus it is usually not of use as a neoadjuvant treatment. Furthermore, 
radiation therapy has not been shown to confer any survival benefit following surgical 
resection as the minimum effective dose is usually too cardio-toxic (Simpson et al., 
2008).  In patients with these non-complicated primary benign tumor types, surgical 
excisions seems to be the most effective primary treatment. Following surgical resection, 
the survival rate for these patients is not statistically different from the general population 
(ElBardissi et al., 2008). Rarely, these benign tumors types can grow in such a way that 
they affect cardiac conduction; a function intrinsic to the heart; or other vital functions of 
the heart. Fortunately, in these cases, when complete resection may not be possible, 
patients with complicated benign PCNs have been shown to benefit from OHT 
(Gowdamarajan & Michler, 2000).   
 Lastly, as shown in Table 3, 25% of patients with primary cardiac neoplasms have 
a malignant tumor type. These tumor types are more aggressive in that they are very 
volatile lesions (i.e. they tend to grow, spread, and invade the cardiac parenchyma more 
quickly than benign tumors). These tumors are known to break off and travel in the blood 
stream to invade distant sites, involve greater portions of the heart tissue than benign 
tumors, and they tend to have multi-centered origination (Meng et al., 2002; Yu et al., 
2014). For these patients chemotherapy and radiation has not been shown to have a 
beneficial effect outside of palliation (Hamidi et al., 2010). In addition, while surgical 
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resection remains the mainstay of conventional treatment, in patients with malignant 
neoplasms, it seems to represent only an effective form of palliation (Hamidi et al., 
2010). Still some report that surgery is the only treatment capable of improving outcome 
even after palliative resection (Llombart-Cussac et al., 1998). Despite this, due to the 
natural unresectability of primary malignant cardiac tumors, prognosis remains poor with 
survival measured in only weeks and months (Silverman, 1980). Finally, while at one 
point orthotopic heart transplant seemed a promising option for these patients, some 
investigators are not sure (Mazuecos et al., 2003). In 2002, Jiménez-Mazuecos and his 
colleagues reported that OHT had emerged as an alternative treatment for these patients. 
However, after failing to demonstrate any survival benefit, the authors concluded that this 
may, in part, be due to other factors. For example, they state that diagnostic techniques 
sensitive enough to discriminate with certainty those patients who would be good 
candidates for OHT did not exist. Further, they note that the role of immunosuppressive 
drugs in tumor recurrence is yet unknown. By 2010, Hamidi et al were still not convinced 
of the efficacy of OHT citing case studies demonstrating that heart transplantation lead 
only to limited improvements in survival (Hamidi et al., 2010). 
As stated above, in 1999, Centofanti and colleagues noted a tumor type effect 
related to the efficacy of conventional treatment. They reported that, “In general, survival 
chances are excellent for patients with myxomas, fair for those with nonmyxomatous 
benign tumors, and dismal for patients with malignant tumors” (Centofanti et al., 1999). 
Over 15 years later, as this review has shown, this trend holds. Thus, for approximately 
38% of the people afflicted with cardiac neoplasms, it can be said that, yes, effective 
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treatments do exist. Conventional therapy has been shown to confer symptom relief and 
significantly increase survival though nothing has been reported on the patients’ post 
treatment quality of life (ElBardissi et al., 2008). On the other hand, these beneficial 
effects have only been reported for certain types of nonmyxomatous benign cardiac 
tumors (Butany et al., 2005). Thus, for the other 37% of patients with primary benign 
heart tumors that have had the misfortune of developing a nonmyxomatous lesions, the 
answer may be a little less definitive. For example, while chemotherapy is effective in 
treating primary cardiac lymphomas it can do little for rhabdomyomas though both are 
benign PCNs  (Sarjeant et al., 2003; Silverman, 1980). Furthermore, while surgical 
resection is generally curative in fibromas it is contraindicated in primary cardiac 
mesotheliomas (ElBardissi et al., 2008; Silverman, 1980). In regards to orthotopic heart 
transplants for these patients, as stated, the efficacy is dependent upon whether or not 
tumor cells are present at the surgical margins. As Goldstein et al reported in 1995, OHT 
provided long term survival to those patients in whom cardiectomy resulted in tumor free 
surgical margins (Dj et al., 1994).   
For the final quarter of all patients stricken with this rare disease, the answer to 
whether or not effective treatments exist seems to be no. In regards to symptom relief 
radiation and chemotherapy may be used in these patients but, as Vander noted, without 
great expectation of success (Tj, 2000). Further, Hamidi et al reported that adjuvant 
radiation therapy did not confer any statistically significant survival benefit and 
Llombart-Cussac et al noted the failure of adjuvant chemotherapy to have any significant 
effect (Hamidi et al., 2010; Llombart-Cussac et al., 1998). While Llombart-Cussac and 
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his colleagues also believed that surgery was the only treatment capable of improving 
outcomes in these patients, Sarjeant and her team noted that these procedures are 
typically not successful as complete resection of malignant cardiac tumors is usually not 
possible (Llombart-Cussac et al., 1998; Sarjeant et al., 2003). Finally, orthoscopic heart 
transplantation has not been shown to be an effective treatment for primary malignant 
heart tumors. After undergoing this high risk operation, these patients’ survival rates were 
very similar to their counterparts who had not undergone the procedure (Mazuecos et al., 
2003). Thus, in regards to symptom relief, increased survival, and increased quality of 
life, neither radiation, chemotherapy, surgical resection, nor orthotopic heart 
transplantation can be shown to be effective. 
 
Next Steps 
Despite this disparaging conclusion, the future may hold greater hope for patients 
with primary cardiac neoplasms. Many investigators have been working to correct the 
tumor type prognostic disparities plaguing a subset of patients with primary cardiac 
neoplasms. Today, cardiac autotransplantation is gaining momentum as the treatment of 
choice for complicated heart tumors. Further more individualized treatments, such as 
targeted gene therapies, have been investigated as possible new treatments for cardiac 
tumors. Finally, many researcher are now looking to directly target the process of 
metastasis which could presage a new age for all metastatic cancers. With the 
development of new technologies and further investigation, these new approaches, as 
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explained below, hold the promise of effective treatment for all patients with primary 
cardiac tumors. 
Cardiac autotransplantation is the process of explanting the heart from the body, 
excising the indicated tumor(s), preforming reconstructions to the heart where necessary, 
and re-implanting the heart into the patient’s thoracic cavity (Reardon, Walkes, DeFelice, 
& Wojciechowski, 2006). During the entire procedure patients are sustained on 
cardiopulmonary bypass while surgeons work to excise the tumor from the cardiac 
muscle tissue (Reardon, DeFelice, Sheinbaum, & Baldwin, 1999). The procedure was 
first introduced to treat complicated benign tumors in 1985 by Cooley et al and, in 1999, 
Reardon and his colleagues used autotransplantation to treat primary malignant cardiac 
tumors (Blackmon et al., 2008). Despite the fact that the first procedure was successfully 
performed approximately 30 years ago, the rarity of primary cardiac neoplasms has 
precluded the thorough investigation of the benefits of this procedure. Further, as 
Blackmon et al report, this rarity leaves institutions and surgeons alike with few cases 
from which to draw conclusions (Blackmon et al., 2008). Since then, however, 
approximately 40 patients have been treated in this way (Ramlawi et al., 2014; Reardon 
et al., 2006; Selman A, Ubilla S, Espinoza H, & Muñoz P, 2012).  
In 2006, Reardon et al released the first case report describing the surgical 
resection of a primary malignant left ventricular tumor via cardiac autotransplantation. 
They did this, they report, in order to overcome the anatomic challenges of left heart 
tumors (Reardon et al., 2006). Due to location, the resection of left heart tumors generally 
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require cutting into healthy cardiac muscle. Therefore, Reardon and his colleagues 
reported, explanting the heart prior to tumor excision allowed excellent exposure of the 
left ventricular cavity and prevented the possible impairment of left ventricular function 
(Reardon et al., 2006). Three years after the surgery, the patient was reported to be well 
with no evidence of recurrent disease (Reardon et al., 2006). Thus, the authors concluded 
that cardiac autotransplantation was a useful approach in the treatment of primary 
malignant heart tumors. 
In 2008, Blackmon et al published an article featuring 20 patients who underwent 
cardiac autotransplantation. In 2014, Ramlawi et al released an updated report describing 
the results of 35 autotransplantation procedures performed in 34 patients; including the 
20 who were featured in the first report. What they found is that the median survival rate 
in patients with primary malignant cardiac tumors undergoing autotransplantation was 22 
months. (Blackmon et al., 2008). This is double the rate reported with conventional 
treatment (Putnam Jr et al., 1991). They also reported that autotransplantation addressed 
many of the shortcomings of orthotopic heart transplantation. First, as Hamidi et al 
feared, the shortage of heart donors can be seen as one of the disadvantages of using 
OHT to treat cardiac tumors (Hamidi et al., 2010). With autotransplantation the donor is 
also the recipient. Thus, in essence, there is a one to one supply and demand ratio. This is 
especially important because, even though Jiménez-Mazuecos et al reported that his 
subjects only spent 8-48 days waiting for donor hearts, in the case of heart tumors every 
second counts. Treating patients as soon as possible prevents the most lethal aspects of 
cardiac tumors such as extracardiac tumor extension, congestive heart failure, heart 
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block, and possible tumor embolization (Blackmon et al., 2008). Due to the success in 
their patient population, Ramlawi et al concluded that cardiac autotransplantation was a 
viable option for obtaining complete tumor resection which is a positive prognostic factor 
(Blackmon et al., 2008; Dj et al., 1994). Further, the authors concluded that 
autotransplantation was ‘feasible and safe technique for resection of complex left-side 
tumors’ (Ramlawi et al., 2014). In addition to solving the problem of donor shortages, 
cardiac autotransplantation also does away with the need for pre- and post- operative 
immunosuppressive therapy. This is especially advantageous in these patients with a 
history of cancer because, as Gowdamarajan et al reported, the role of 
immunosuppressive therapies in tumor recurrence is still not known (Gowdamarajan & 
Michler, 2000). Thus, not only do we eliminate the risk of promoting tumor recurrence 
we also prevent the development of cardiac adiposity which is a precursor to pericardial 
effusion in patients whose immunosuppressive agent is a corticosteroid (Roberts, 2001). 
Further, eliminating the need for immunosuppressive therapy gives researchers a control 
group off which to base the further investigation of immunosuppression as a tumor 
promoting agent. In a randomized control trial it would be feasible to measure the time to 
recurrence in patients treated with orthotopic heart transplantation and subsequent 
immunosuppression versus the time to tumor recurrence in those patients treated with 
cardiac autotransplantation without subsequent immunosuppression. In this way, the link 
between tumor recurrence and immunosuppressive agents could either be established or 
confidently invalidated. Either way, clinicians would be better able to treat their patients 
with the full knowledge of all of the possible consequences of each respective therapy. 
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Another promising new approach to cardiac tumor treatment is targeted gene 
therapy. While this from of treatment is not new to the field of medicine, it has not been 
thoroughly investigated as a primary form of treatment for cardiac tumors. According to 
some authors, such treatments could be administered as part of a multifaceted approach to 
the treatment of the most clinically aggressive lesions (Neragi-Miandoab, Kim, & 
Vlahakes, 2007).  As stated in Neragi-Miandoab et al’s 2007 article, advancements in 
molecular biology has revealed some reproducible genetic translocations in cancer cells 
that could serve as targets for new drugs (Neragi-Miandoab et al., 2007). In vivo these 
translocations can give rise to the intermediate steps that cause malignant changes within 
normal cells. With the knowledge of such translocations in mind, investigators and 
clinicians alike would have a more specified target in the treatment of certain cancers. 
With the development of such drugs it may then be possible to avoid some of the 
widespread effects of certain conventional chemotherapeutic agents. For example, one 
translocation that has been noted in some cancers is the translocation of chromosome 12 
and 15. This rearranging of the chromosomes causes a transcription factor to fuse with a 
tyrosine kinase yielding a product that has oncogenic potential (Neragi-Miandoab et al., 
2007). In such cases tyrosine kinase inhibitors may prove effective in slowing the 
progression of the disease. Further, the over expression of the mdm-2 gene, an oncogene 
that binds and inhibits the tumor suppressor gene p53, has been seen in many sarcomas 
(Neragi-Miandoab et al., 2007). These high levels of mdm-2 are associated with, among 
other things, angiogenesis which is crucial to the persistence and possible metastasis of 
cancer cells (Neragi-Miandoab et al., 2007). Thus, medications that target these this gene 
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could prove effective in the treatment of sarcomas which, in the heart, account for 
approximately 20% of primary malignant cardiac neoplasms. Despite all of the 
information we now have on these and other possible targets for anti-cancer drugs, a lot 
more work is required to prove their efficacy and safety for use in humans and in the 
heart. As Neragi-Miandoab et al stated, more clinical studies are needed before these 
approaches can be effectively included in the neoadjuvant or adjuvant treatment of 
cardiac tumors (Neragi-Miandoab et al., 2007). 
In closing, as stated above, there is much work to be done before we can ever 
hope to arrive at therapies that can effectively treat complicated benign and malignant 
forms of primary cardiac neoplasms. We need studies that will further the investigation of 
some of the newer treatment modalities and characterize their potential benefits in the 
treatment of heart tumors. This will help us to know where our efforts are best spent. 
Further, we need researchers and engineers working towards discovering more and more 
specific genetic targets for anti-cancer drugs which will prevent the adverse systemic side 
effects currently associated with conventional therapy. We need the comprehensive 
implementation of currently available therapies, such as cardiac autotransplantation, for 
the purpose of proving or disproving their clinical efficacy. Moreover, we need studies 
that will collect, characterize, and compare data on the quality of life of patients with 
primary cardiac neoplasms treated with the various treatment modalities. Finally, there 
must be investigators who will consider the more occult causes and treatments for cancer. 
For example, with the knowledge that inflammatory responses play decisive roles in the 
various stages of tumor development, it may be worthwhile to begin to develop anti-
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inflammatory and immune stimulatory cancer therapies (Grivennikov, Greten, & Karin, 
2010). In so doing, the continued efforts put forth by these groups will lead to a greater 
hope for patients who’s PCNs are not easily treated with conventional therapies.  
Eventually with continued investigation, these promising therapeutic techniques will be 
used to afford symptom relief, increased survival, and a better quality of life to patients 
whose primary heart tumors are either complicated or malignant. In the end, with the 
further development of these therapies, it is our hope that effective treatment will be 
available for all patients with primary cardiac neoplasms regardless of the etiology and/ 
or the histology of the respective diseases. 
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